Want to see SE:NEOLA full AI Analyst Report?
NEOLA Stock Chart & Stats
kr0.58
kr0.02(3.45%)
At close: 4:00 PM EDT
kr0.58
kr0.02(3.45%)
Day’s Range― - ―
52-Week Rangekr0.47 - kr2.32
Previous CloseN/A
Volume49.06K
Average Volume (3M)12.79K
Market Cap
kr54.58M
Enterprise Valuekr64.18
Total Cash (Recent Filing)kr16.12M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding110,476,940
10 Day Avg. Volume10,323
30 Day Avg. Volume12,794
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.07
Price to Sales (P/S)0.00
P/FCF Ratio-3.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr10.00M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetZero reported debt limits interest and refinancing risk, preserving financial flexibility while Neola develops its product. This gives the company a stronger solvency position than a similarly unprofitable medtech issuer carrying significant leverage.
Equity CushionA meaningful equity base provides some capacity to fund product development and commercialization before revenues scale. Although losses can erode it, the current cushion reduces immediate balance-sheet stress and supports continued execution.
Specialized Neonatal FocusA focused neonatal-monitoring proposition addresses a specialized clinical need and may support differentiated product development. If validated and adopted, continuous non-invasive lung and breathing monitoring could create a defensible niche in neonatal care.
Bears Say
No Revenue TractionPersistent near-zero revenue indicates that commercialization has not yet translated into a functioning revenue base. This leaves the investment case dependent on future regulatory, clinical and hospital adoption milestones rather than demonstrated operating demand.
Persistent LossesOngoing losses, with no clear profitability inflection, show that development and operating costs are not yet covered by business activity. Continued losses could reduce equity and increase reliance on future financing if commercialization remains delayed.
Negative Operating Cash FlowNegative operating cash flow confirms that the core business is not self-funding. Even with no debt, continued cash consumption can shorten financial flexibility and make future product development dependent on equity funding or a successful revenue ramp.
Neola Medical AB News
NEOLA FAQ
What was Neola Medical AB’s price range in the past 12 months?
Neola Medical AB lowest stock price was kr0.47 and its highest was kr2.32 in the past 12 months.
What is Neola Medical AB’s market cap?
Neola Medical AB’s market cap is kr54.58M.
When is Neola Medical AB’s upcoming earnings report date?
Neola Medical AB’s upcoming earnings report date is Nov 18, 2026 which is in 82 days.
How were Neola Medical AB’s earnings last quarter?
Neola Medical AB released its earnings results on Aug 20, 2026. The company reported -kr0.048 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Neola Medical AB overvalued?
According to Wall Street analysts Neola Medical AB’s price is currently Overvalued.
Does Neola Medical AB pay dividends?
Neola Medical AB does not currently pay dividends.
What is Neola Medical AB’s EPS estimate?
Neola Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neola Medical AB have?
Neola Medical AB has 110,476,940 shares outstanding.
What happened to Neola Medical AB’s price movement after its last earnings report?
Neola Medical AB reported an EPS of -kr0.048 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.009%.
Which hedge fund is a major shareholder of Neola Medical AB?
Currently, no hedge funds are holding shares in SE:NEOLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neola Medical AB
Neola Medical AB (publ) specializes in developing advanced medical devices for the continuous pulmonary assessment of premature babies. At the core of its offerings is NEOLA, a sophisticated medical instrument critical for neonatal intensive care. This device facilitates ongoing lung function monitoring and generates immediate alerts for critical, life-threatening complications. It achieves this by accurately tracking changes in lung volume and oxygen gas concentration. The ultimate goal of NEOLA is to enhance intensive care and promote healthier outcomes for infants born preterm. The company, formerly known as GPX Medical AB, officially changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was established in 2016 and is headquartered in Lund, Sweden.